Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Other Accumulated Expenses (2020 - 2022)

Ovid Therapeutics (OVID) has disclosed Other Accumulated Expenses for 3 consecutive years, with $139167.0 as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Other Accumulated Expenses fell 79.33% year-over-year to $139167.0, compared with a TTM value of $139167.0 through Mar 2022, down 79.33%, and an annual FY2021 reading of $546464.0, up 230.12% over the prior year.
  • Other Accumulated Expenses was $139167.0 for Q1 2022 at Ovid Therapeutics, down from $546464.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.0 million in Q2 2021 and bottomed at $119940.0 in Q3 2021.
  • Average Other Accumulated Expenses over 3 years is $488409.9, with a median of $271314.0 recorded in 2020.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 621.03% in 2021, then tumbled 79.33% in 2022.
  • Year by year, Other Accumulated Expenses stood at $165536.0 in 2020, then surged by 230.12% to $546464.0 in 2021, then tumbled by 74.53% to $139167.0 in 2022.
  • Business Quant data shows Other Accumulated Expenses for OVID at $139167.0 in Q1 2022, $546464.0 in Q4 2021, and $119940.0 in Q3 2021.